A review of nursing quality assessment tools identified characteristics of commonly used instruments to measure nurse ...

Researchers sought to determine whether combining enasidenib with venetoclax would be effective in patients with IDH2-mutated ...

By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.

Alpelisib/Fulvestrant combo improves OS, PFS for patients with previously-treated PIK3CA-Mutated, HR+, HER2− advanced breast cancer ...

HealthDay News — Nearly one-third of families of children receiving chemotherapy for acute lymphoblastic leukemia (ALL) develop serious financial difficulties during their child’s treatment, according ...

Intensity-modulated proton therapy (IMPT) improves overall survival (OS) and reduces high-grade toxicity compared with intensity-modulated radiation ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...

In the PREFER trial, researchers aimed to investigate and assess the safety of strategies for fertility preservation in ...

The BOOG 2013-08 trial evaluates whether SLNB can be safely omitted for patients with clinically T1-2N0 treated with ...

Researchers examined the long-term natural history of branch-duct intraductal papillary mucinous neoplasms and sought to identify clinical and radiologic factors linked to developing pancreatic cancer ...

Relieving venous congestion using thrombectomy may preserve kidney function in RCC with IVC tumor thrombus.

PSMAddition is an international, open-label, prospective, phase 3 randomized controlled trial of 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC.